BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 18617782)

  • 1. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir.
    Leemans WF; Niesters HG; van der Eijk AA; Janssen HL; Schalm SW; de Man RA
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):773-7. PubMed ID: 18617782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral dynamics during tenofovir therapy in patients infected with lamivudine-resistant hepatitis B virus mutants.
    van der Eijk AA; Hansen BE; Niesters HG; Janssen HL; van de Ende M; Schalm SW; de Man RA
    J Viral Hepat; 2005 Jul; 12(4):364-72. PubMed ID: 15985006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.
    Choe WH; Hong SP; Kim BK; Ko SY; Jung YK; Kim JH; Yeon JE; Byun KS; Kim KH; Ji SI; Kim SO; Lee CH; Kwon SY
    Antivir Ther; 2009; 14(7):985-93. PubMed ID: 19918102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Suzuki Y; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Miyakawa Y; Kumada H
    J Gastroenterol Hepatol; 2009 Mar; 24(3):429-35. PubMed ID: 19226381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.
    Chang TT; Gish RG; Hadziyannis SJ; Cianciara J; Rizzetto M; Schiff ER; Pastore G; Bacon BR; Poynard T; Joshi S; Klesczewski KS; Thiry A; Rose RE; Colonno RJ; Hindes RG;
    Gastroenterology; 2005 Oct; 129(4):1198-209. PubMed ID: 16230074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.
    Gish RG; Lok AS; Chang TT; de Man RA; Gadano A; Sollano J; Han KH; Chao YC; Lee SD; Harris M; Yang J; Colonno R; Brett-Smith H
    Gastroenterology; 2007 Nov; 133(5):1437-44. PubMed ID: 17983800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
    Villet S; Ollivet A; Pichoud C; Barraud L; Villeneuve JP; Trépo C; Zoulim F
    J Hepatol; 2007 Mar; 46(3):531-8. PubMed ID: 17239478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
    Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
    Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.
    Lai CL; Rosmawati M; Lao J; Van Vlierberghe H; Anderson FH; Thomas N; Dehertogh D
    Gastroenterology; 2002 Dec; 123(6):1831-8. PubMed ID: 12454840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient.
    Guo JJ; Li QL; Shi XF; Zhang DZ; Zeng AZ; Feng T; Huang AL
    Antiviral Res; 2009 Feb; 81(2):180-3. PubMed ID: 18948142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
    Shouval D; Lai CL; Chang TT; Cheinquer H; Martin P; Carosi G; Han S; Kaymakoglu S; Tamez R; Yang J; Tenney D; Brett-Smith H
    J Hepatol; 2009 Feb; 50(2):289-95. PubMed ID: 19070393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B.
    Sherman M; Yurdaydin C; Sollano J; Silva M; Liaw YF; Cianciara J; Boron-Kaczmarska A; Martin P; Goodman Z; Colonno R; Cross A; Denisky G; Kreter B; Hindes R;
    Gastroenterology; 2006 Jun; 130(7):2039-49. PubMed ID: 16762627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
    N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus.
    Dore GJ; Cooper DA; Pozniak AL; DeJesus E; Zhong L; Miller MD; Lu B; Cheng AK; ;
    J Infect Dis; 2004 Apr; 189(7):1185-92. PubMed ID: 15031786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
    Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L;
    N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy.
    Reijnders JG; Pas SD; Schutten M; de Man RA; Janssen HL
    J Hepatol; 2009 Apr; 50(4):674-83. PubMed ID: 19231002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
    Alvarez-Uria G; Ratcliffe L; Vilar J
    HIV Med; 2009 May; 10(5):269-73. PubMed ID: 19210695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
    Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
    Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.